TGTX vs PCVX
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
TGTX · TG Therapeutics$59.83 ▲ 3.18%
PCVX · Vaxcyte$63.89 ▲ 3.18%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- TGTX +97.4%
- PCVX +48.9%
Head to head
| Metric | TGTX | PCVX |
|---|---|---|
| Price | $59.83 | $63.89 |
| Change today | ▲ 3.18% | ▲ 3.18% |
| Market cap | $9.16B | $10.11B |
| Return, 3 months | +21.7% | +9.6% |
| Return, year to date | +100.7% | +38.5% |
| Return, 1 year | +85.6% | +53.4% |
| P/E (TTM) | 21.8 | – |
| P/B | 15.2 | 4.1 |
| P/E percentile vs own 5y | 73rd | 88th |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | +70.3% | – |
| Net profit growth (YoY) | -72.4% | -70.7% |
| Gross margin | 82.4% | – |
| Operating margin | 17.1% | – |
| Net margin | 55.2% | – |
| Return on equity | 100.3% | -36.5% |
| Analyst target vs. price | +8.7% | +92.1% |
| Analyst buy share | 80% | 88% |
| RSI (14) | 59 | 53 |
| 30-day volatility | 40.4% | 100.2% |
| Max drawdown, 1 year | -22.5% | -28.0% |
| Trend read | Strong uptrend | Strong uptrend |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- PCVX is the largest of the group by market value.
- TGTX has returned the most over the past year.
- TGTX has been the calmest stock over the last 30 days.